Regulatory T cells-An important target for cancer immunotherapy

Nature Reviews Clinical Oncology

Volumn 11, Issue 6, 2014, Pages 307-

  Shin, Jae Il ^a   Ha, Sang Jun ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DENILEUKIN DIFTITOX; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; HUMAN; LETTER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR REGRESSION;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; MOLECULAR TARGETED THERAPY;

EID: 84902009526     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.208-c1     Document Type: Letter

References (13)

1. Drake, C. G., Lipson, E. J. & Brahmer, J. R. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 11, 24-37 (2014).
2. Waldmann, T. A. Effective cancer therapy through immunomodulation. Annu. Rev. Med. 57, 65-81 (2006).
3. Pandolfi, F. et al. Strategies to overcome obstacles to successful immunotherapy of melanoma. Int. J. Immunopathol. Pharmacol. 21, 493-500 (2008).
4. Wang, W. et al. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int. Immunol. 21, 1065-1077 (2009).
5. Sharma, M. D. et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 2570-2582 (2007).
6. Kavanagh, B. et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112, 1175-1183 (2008).
7. Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013).
8. Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271-275 (2008).
9. Sakaguchi, S. et al. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490-500 (2010).
10. Sugiyama, D. et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumour immune responses in humans. Proc. Natl Acad. Sci. USA 110, 17945-17950 (2013).
11. Pere, H. et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumour immunity against self antigens. Blood 118, 4853-4862 (2011).
12. Zhou, Q. et al. Program death-1 signalling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116, 2484-2493 (2010).
13. Goding, S. R. et al. Restoring immune function of tumour-specific CD4+ T cells during recurrence of melanoma. J. Immunol. 190, 4899-4909 (2013).